Skip to main content

Advertisement

SpringerLink
Log in

Safety of total thyroid ablation in patients with Graves’ orbitopathy

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bartalena L, Tanda ML (2009) Clinical practice—Graves’ ophthalmopathy. N Engl J Med 360:994–1001. doi:10.1056/NEJMcp0806317

    Article  CAS  PubMed  Google Scholar 

  2. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98:1443–1449. doi:10.1210/jc.2012-3873

    Article  CAS  PubMed  Google Scholar 

  3. Bartalena L, Fatuorechi V (2014) Extrathyroidal manifestations of Graves’ disease. J Endocrinol Investig 37:691–700

    Article  CAS  Google Scholar 

  4. Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2015) Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Investig 38:283–294. doi:10.1007/s40618-014-0214-2

    Article  Google Scholar 

  5. Wiersinga WM (2011) Autoimmunity in Graves’ ophthalmopathy: The result of an unfortunate marriage between TSH receptors and IGF-1 receptors? JCEM 96:2386–2394. doi:10.1210/jc.2011-0307

    CAS  PubMed  Google Scholar 

  6. Bahn RS (2015) Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 47:773–778. doi:10.1055/s-0035-1555762

    Article  CAS  PubMed  Google Scholar 

  7. Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) Thyrotropin/IGF-1 receptor crosstalk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab 4:jc20161315

    Google Scholar 

  8. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A (2003) Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139:346–351

    Article  CAS  PubMed  Google Scholar 

  9. Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F (2015) Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrinol Investig 38:481–487. doi:10.1007/s40618-015-0257-z

    Article  CAS  Google Scholar 

  10. Menconi F, Leo M, Vitti P, Marcocci C, Marinò M (2015) Total thyroid ablation in Graves’ orbitopathy. J Endocrinol Investig 38:809–815. doi:10.1007/s40618-015-0255-1

    Article  CAS  Google Scholar 

  11. Moleti M, Mattina F, Salamone I, Violi MA, Nucera C, Baldari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F (2003) Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves’ ophthalmopathy. Thyroid 13:653–658. doi:10.1089/105072503322240004

    Article  PubMed  Google Scholar 

  12. Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92:1653–1658. doi:10.1210/jc.2006-1800

    Article  CAS  PubMed  Google Scholar 

  13. Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G, Presti S, Alibrandi A, Campennì A, Baldari S, Trimarchi F, Vermiglio F (2014) Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves’ orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J Clin Endocrinol Metab 99:1783–1789. doi:10.1210/jc.2013-3093

    Article  CAS  PubMed  Google Scholar 

  14. Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marinò M (2012) Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 97:E44–E48. doi:10.1210/jc.2011-2077

    Article  CAS  PubMed  Google Scholar 

  15. Bartalena L (2011) The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96:592–599. doi:10.1210/jc.2010-2329

    Article  CAS  PubMed  Google Scholar 

  16. Berg G, Andersson T, Sjödell L, Jansson S, Nyström E (2005) Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid. Thyroid 15:1389–1394. doi:10.1089/thy.2005.15.1389

    Article  PubMed  Google Scholar 

  17. Daumerie C, Boschi A, Perros P (2012) Is recombinant human TSH a trigger for Graves’ Orbitopathy? Eur Thyroid J 1:105–109. doi:10.1159/000338038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rocchi R, Altea MA, Marinò M, Menconi F, Leo M, Sisti E, Profilo MA, Lepri P, Marco Nardi M, Vitti P, Marcocci C, Latrofa F (2015) Optic neuropathy in 2 thyroidectomized patients with moderate to severe graves ophthalmopathy following l-thyroxine withdrawal prior to radioiodine treatment for thyroid carcinoma. AACE Clin Case Rep 1:e119–e122. doi:10.4158/EP14276.CR

    Article  Google Scholar 

  19. van Zeijl CJ, Fliers E, van Koppen CJ, Surovtseva OV, de Gooyer ME, Mourits MP, Wiersinga WM, Miltenburg AM, Boelen A (2010) Effects of thyrotropin and thyrotropin-receptor-stimulating Graves’ disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves’ ophthalmopathy patients. Thyroid 20:535–544. doi:10.1089/thy.2009.0447

    Article  PubMed  Google Scholar 

  20. van Zeijl CJ, Fliers E, van Koppen CJ, Surotseva OV, de GooyerME MouritsMP, WiersingaWM MiltenburgAM, Boelen A (2011) Thyrotropin receptor-stimulating Graves’ disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves’ ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways. Thyroid 21:169–176. doi:10.1089/thy.2010.0123

    Article  PubMed  Google Scholar 

  21. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci M, Perros P, Salvi M, Wiersinga WM on behalf of the European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26. doi:10.1159/000443828

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:320–332. doi:10.1210/jc.2010-1962

    Article  CAS  PubMed  Google Scholar 

  23. Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campennì A, Morelli S, Puxeddu E, Sisti E, Trimarchi F, Vermiglio F, Marinò M (2016) Acute liver damage following intravenous glucocorticoid treatment for Graves’ ophthalmopathy. Endocrine. doi:10.1007/s12020-016-0928-3 (Epub ahead of print)

    Google Scholar 

  24. Pellegriti G, Mannarino C, Russo M, Terranova R, Marturano I, Vigneri R, Belfiore A (2013) Increased mortality in patients with differentiated thyroid cancer associated with Graves’ disease. J Clin Endocrinol Metab 98:1014–1021. doi:10.1210/jc.2012-2843

    Article  CAS  PubMed  Google Scholar 

  25. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for Adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. doi:10.1089/thy.2015.0020

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Clinica e Sperimentale, University of Messina, Messina, Italy

    M. Moleti, G. Sturniolo & F. Vermiglio

  2. Dipartimento di Patologia Umana dell’adulto e dell’età evolutiva “Gaetano Barresi”, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy

    G. Sturniolo

Authors
  1. M. Moleti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Sturniolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Vermiglio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Vermiglio.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

No informed consent is required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moleti, M., Sturniolo, G. & Vermiglio, F. Safety of total thyroid ablation in patients with Graves’ orbitopathy. J Endocrinol Invest 39, 1199–1201 (2016). https://doi.org/10.1007/s40618-016-0485-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-016-0485-x

Keywords

Search

Navigation